Gayatri C. Patel

Raloxifene hydrochloride (RLX), used in post-menopausal osteoporosis, is a class–II drug as per Biopharmaceutics Classification System. The purpose of this research was to formulate modified liquisolid compacts (MLSC) of RLX for improved dissolution in immediate-release tablet formulations. Preliminary trials on selection of excipients were performed. Fourier transform infrared spectra illustrated no interaction between drug and MLSC powder. The X-ray diffraction studies demonstrated the transformation of the crystalline nature of drug into partial amorphous state in MLSC. After all experimental results on selection of excipients were analyzed, the final tablet formulation was derived and manufactured. The results of an in-vitro drug release study from the selected batch illustrated a remarkable improvement in the dissolution rate as compared to reference product. An accelerated stability study as per the ICH Q1 (R2) guideline of the optimized batch was performed for six months and showed no significant change in critical quality attributes of formulation.

Submitted: August 26, 2020
Accepted: December 15, 2020

 is Professor, gayatripatel26@gmail.com, 

 is Research Scholar, all at Charotar University of Science and Technology, Ramanbhai Patel College of Pharmacy, Department of Pharmaceutics & Pharmaceutical Technology, CHARUSAT Campus, Changa- 388421, Gujarat, India.

 is Director at Graduate School of Pharmacy, Gujarat Technological University, Gandhinagar Campus, Nr. Government Polytechnic K-6 Circle, Sector - 26, Gandhinagar-382028, Gujarat, India.

*To whom all correspondence should be addressed.


Volume 45, Number 7
July 2017
Pages: 48-52

When referring to this article, please cite it as G. Patel et al., "Formulation of Modified Liquid-Solid Compact for Dissolution Enhancement of Raloxifene Hydrochloride," 

Articles

The purpose of this research was to formulate modified liquisolid compacts (MLSC) of RLX for improved dissolution in immediate-release tablet formulations.

Formulation of Modified Liquid-Solid Compact for Dissolution Enhancement of Raloxifene Hydrochloride

Cetirizine dihydrochloride (CTZ) is a second-generation piperazine derivative, a potent H1 selective antihistaminic agent. Its extreme bitter taste results in poor patient compliance. The aim of this study was to prepare taste-masked drug-resin complex (DRC) using ion exchange resin Kyron T-134. The DRC was evaluated for effect of variables such as resin ratio, pH, temperature, soaking time of resin, and stirring time on drug loading and taste. Reconstitutable suspension was prepared using drug-resin complex and other pharmaceutical excipients in suspension. Formulated reconstitutable suspension was evaluated for parameters before reconstitution, such as flow properties and drug content, and after reconstitution, such as aesthetic appeal, sedimentation rate, redispersibility, particle size, viscosity, pH, drug content, and 

dissolution study. During the evaluation period of 14 days, no significant change was observed in pH, viscosity, particle size, and drug content. From the results, it is concluded that effective taste masking of CTZ was achieved using Kyron T-134 and successfully evaluated in reconstitutable suspension.

	Submitted: Jan. 28, 2019
	Accepted: Aug. 16, 2019

, gayatripatel.ph@charusat.ac.in, is associate professor at Ramanbhai Patel College of Pharmacy, Charotar University of Science & Technology, Gujarat, India.

To whom all correspondence should be addressed.


	Vol. 44, No. 1
	January 2020
	Pages: 48–52

	When referring to this article, please cite it as G.C. Patel, “Development of Taste-Masked Oral Reconstitutable Suspension of Cetirizine Dihydrochloride,”

The aim of this study was to prepare taste-masked drug-resin complex using ion exchange resin Kyron T-134.